These defensive companies have characteristics that can protect them from any economic and market turbulence, according to Wall Street analysts.. The main buying opportunities for the second half of 2022 are:
The actions of Amazon (AMZN) are down 34% this year, but Jefferies analyst Brent Thill said in a note that investors should not give up the shares of the company. In fact, Thill expects a great second half for the e-commerce giant. He expects the stock to outperform by the end of the year and cited a host of positive catalysts for his thesis, including easier comparisons with last year’s results, strong growth in Amazon Web Services and discounts on multiples. Ecommerce traffic is down on many retail platforms, but Thill’s advice is to stay calm and take advantage of a “rare buying opportunity”, especially if stocks remain on the edge of the range.
The denim company was recently named by Bank of America as one of the best options of the second semestersaid the firm in a recent note that “There is no shortage of positive catalysts for Levi’s”. Analyst Christopher Nardone said that BofA believes that Levi’s (LEVI) has multiple growth engines for “help navigate this challenging consumer landscape”. The number of company stores continues to grow and Nardone expects Levi’s to quickly gain market share.
“Other growth drivers include achieving higher penetration, international expansion and its recent acquisition of Beyond Yoga,” the analyst added.
Nardone praised Levi’s strong management and noted that the company is well positioned to weather an economic storm and has an experienced team to do so successfully.
Other Stocks Mentioned by Wall Street Analysts
Pioneer Resources (PXD)which Goldman Sachs suggests has an “attractive advantage” since “the poor performance represents a good entry pointespecially with stocks trading around 15% dividend yield per year,” according to the bank’s annual estimates for the natural resource exploration company in 2022-2024.Morgan Stanley suggested AbbVie (ABBV), Eli Lilly (LLY) Y Royalty Pharma (RPRX) because “during previous recessions, the historical growth of the volume of drugs in the United States. Therefore, the bank expects that biofarm revenues remain resilient even if economic activity slows.Kroger (KR)as Scotiabank points out, “it stood out from the competitive set and strengthened its position in the market”. The focused execution of the retail business, the strict cost control and competitive advantagesincluding data and private labels, allow Kroger to continue to strategically invest in pricing to drive long-term business, according to the bank.
Disclaimer: The information found on CryptoReport is that of the cited writers. It does not represent the opinions of Criptoinforma on whether to buy, sell or hold investments. You are advised to conduct your own research before making any investment decisions. Use the information provided at your own risk.
Buy and sell Bitcoin and other cryptocurrencies on Binance, the most comprehensive cryptocurrency exchange to safely and conveniently invest in the world’s most traded cryptocurrencies. Sign up and see how simple it is, go to: https://binance.com